Cancer Vaccine Institute News

Photos from the October 23rd event include: Dr. Nora Disis (CVI Director), Dr. Robert Jones (University of Washington President), Dr. Lynn Hassan Jones, Dr. Tim Dellit (UW Medicine CEO), Jean Enersen (Former KING5 News Anchor), Pramila Jayapal (US House of Representatives), Susan Bevan (CVI Development Council Member) October was a powerful month at the University of Washington, as Husky Athletics partnered with the Huskies for a Cure  campaign to raise awareness and funds f

Last week at the Cancer Vaccine Institute, we witnessed a moment of joy, pride, and profound recognition as Dr. Nora Disis was honored as a Delta Community Captain . In a surprise event filled with CVI lab members, Seahawks representatives, Delta Air Lines team members, and Dr. Disis’ family, the room erupted in celebration of a scientist whose work is transforming the future of breast cancer care. The Delta Community Captain program, powered by Delta Air Lines in partnership

Developing Vaccines to Create a New Standard of Care On October 22, 2025, the Cancer Vaccine Institute (CVI) at UW Medicine welcomed patients, advocates, researchers, and community members to DeLille Cellars in Woodinville, WA for an evening of connection and discovery. “Changing the Course of Ovarian Cancer” highlighted how cancer vaccines, once considered aspirational, are now changing lives and redefining what’s possible in cancer care. Driving a New Standard of Care The e

We are thrilled to announce that Dr. Natasha Hunter, MD, has been appointed Director of Clinical Trials at the Cancer Vaccine Institute (CVI). Dr. Hunter is a translational breast cancer researcher and clinical oncologist at the University of Washington and Fred Hutchinson Cancer Center. Her research focuses on circulating tumor DNA to guide treatment decisions and monitor disease response, as well as immunologic strategies to detect micrometastatic disease and prevent cancer

We are proud to announce that Dr. Nora Disis, Director of the Cancer Vaccine Institute, has been selected as a 2025 Champion of SITC by the Society for Immunotherapy of Cancer (SITC). This special recognition, part of SITC’s 40th anniversary celebration, honors 40 individuals whose work has significantly advanced the society’s mission—including education, scientific exchange, global access, advocacy, and leadership development. Dr. Disis’ pioneering contributions to cancer va